Creabilis appoints new chief executive

Eliot Forster brings significant drug development experience to firm

Creabilis, a clinical stage European biotechnology company addressing significant unmet medical needs in dermatological diseases, has appointed Eliot Forster as its new chief executive.

Forster brings almost 20 years’ industry experience in biotechnology and pharmaceutical companies to the Luxembourg-based firm.

He was most recently chief executive of Solace Pharmaceuticals, a US-based biotech. Prior to this, was Pfizer’s head of EU development and of development operations in the EU and Asia. During his career at Pfizer Forster was integral to bringing a number of drugs to market, including Celebrex (celecoxib), Bextra (valcecoxib) and Relpax (eletriptan).

Creabilis’ lead product is CT327, a novel topically applied TrkA kinase inhibitor developed using the Company’s LSE (Low Systemic Exposure) technology. It is currently in Phase II clinical trials in psoriasis and atopic dermatitis.

The Creabilis portfolio also includes CT637, a new approach to the treatment of significant inflammatory conditions such as rheumatoid arthritis as well as severe psoriasis.

You may also like

Finance

Creabilis establishes UK operation

Location in Kent broadens the county’s links with the pharma industry
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth
Research & Development

Hamilton Health Sciences chosen for BirchBioMed burn scar treatment trial

BirchBioMed announces Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario as the first contracted clinical trial site for its Phase II/III randomised study of the naturally based compound: FS2.
Research & Development

Indena and TCG GreenChem join forces to advance next-generation ADC technologies

Indena and TCG GreenChem are pleased to announce a new strategic collaboration aimed at accelerating the development of innovative and market-ready payload-linkers: the key component of antibody-drug conjugates (ADCs)
Subscribe now